- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06025292
Effects of Lean Pork Loin Intake on Protein Homeostasis and Glucose Regulation in Prediabetic Adults (PORK)
We will be directly comparing a high-quality protein diet composed primarily of lean pork loin (PORK) to a lower-quality plant-based protein diet (PLANT) in individuals with prediabetes on muscle and whole-body protein turnover and glucose regulation.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: David Church, PhD
- Phone Number: 501-526-5769
- Email: dchurch@uams.edu
Study Contact Backup
- Name: Amanda Gwin, PA-C
- Phone Number: 5018380096
- Email: algwin@uams.edu
Study Locations
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72205
- Recruiting
- University of Arkansas for Medical Sciences
-
Contact:
- David D Church, PhD
- Email: dchurch@uams.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- 1. Males and females ages 40-65 years.
- 2. BMI 25 to ≤40 kg/m2 (or body fat % ≥25% in males or ≥36% in females)
- 3. Capable of providing informed consent.
- 4. COVID-19 negative and/or asymptomatic.
- 5. Willing to abstain from drinking alcohol or consuming marijuana and CBD products during the 4-day study meal period
- 6. HbA1c: 5.7-6.4% or fasting glucose 100-125 mg/dL
Exclusion Criteria:
- 1. Participant who does not/will not eat animal protein sources.
- 2. Allergy to wheat, soy, or common ingredients in plant-based protein products.
- 3. Body mass index <25 kg/m2 or >40 kg/m2.
- 4. Hemoglobin <10g/dL at screening.
- 5. Platelets <150,000/uL at screening.
- 6. History of chemotherapy or radiation therapy for cancer in the 6 months prior to enrollment.
- 7. History of gastrointestinal bypass/reduction surgery.
- 8. Pregnant or lactating individuals.
- 9. History of a chronic inflammatory disease (e.g. Lupus, Crohn's disease)
- 10. Currently receiving androgen (e.g., testosterone) or anabolic (e.g., GH, IGF-I) therapy.
- 11. Currently using prescription blood thinning medications.
- 12. Currently using corticosteroid medications (cortisone, hydrocortisone, prednisone, etc.).
- 13. Unable or unwilling to suspend aspirin use for 7 days prior to Visit 3 and Visit 7.
- 14. Unwilling to avoid using protein or amino-acid supplements during participation.
- 15. Unwilling to fast overnight.
- 16. Unwilling to avoid alcohol, marijuana and CBD products for the four study days.
- 17. Participants on glucagon-like-peptide-1 receptor agonist (GLP-1-RA) medications for <1 month or with less than one treatment dose (injection) every two weeks
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: High Quality Protein Intake - Lean Pork
Meal patterns will mimic a standard American diet (50% carbohydrate, 15% protein, 35% fat), providing an isonitrogenous 0.8 g/kg/d protein, and meeting individual estimated daily energy requirements. We have chosen 0.8 g/kg/d as it is the recommend dietary allowance for protein in the US. This arm's protein source will be from lean pork. |
Participants will eat prepared study meals for three days that have either protein sourced from lean pork or plant-based sources. |
|
Active Comparator: Low Quality Protein Intake - Plant-Based
Meal patterns will mimic a standard American diet (50% carbohydrate, 15% protein, 35% fat), providing an isonitrogenous 0.8 g/kg/d protein, and meeting individual estimated daily energy requirements. We have chosen 0.8 g/kg/d as it is the recommend dietary allowance for protein in the US. This arm's protein source will be from plant-based protein (ie impossible burger, black bean burger, soy, etc). |
Participants will eat prepared study meals for three days that have either protein sourced from lean pork or plant-based sources. |
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Muscle Protein Synthesis
Time Frame: 24 hours
|
Mixed muscle protein synthesis expressed as the fractional synthetic rate. |
24 hours
|
|
Whole Body Protein Balance
Time Frame: 24 hours
|
Amount of net protein gained per unit of time. |
24 hours
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Whole Body Protein Synthesis
Time Frame: 24 hours
|
Amount of protein produced per unit of time. |
24 hours
|
|
24-hour Mean Glucose
Time Frame: 24 hours
|
Derived from continous glucose monitor data. |
24 hours
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Whole Body Protein Breakdown
Time Frame: 24 hours
|
Amount of protein broken down per unit of time. |
24 hours
|
|
Whole Body Protein Flux
Time Frame: 24 hours
|
Amount of protein turnover per unit of time. |
24 hours
|
|
Glucose Regulation and Homeostasis
Time Frame: 24 hours
|
Derived from continuous glucose monitor data. |
24 hours
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Church, PhD, University of Arkansas
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 276210
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.